# Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors

> **NCT02665416** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 94 (actual)

## Conditions studied

- Advanced/Metastatic Solid Tumors

## Interventions

- **DRUG:** Selicrelumab
- **DRUG:** Vanucizumab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT02665416
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-25
- **Primary completion:** 2019-10-30
- **Final completion:** 2019-10-30
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2020-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02665416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02665416, "Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02665416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*